BOZO RESEARCH CENTER

What BOZO RESEARCH CENTER does

BOZO RESEARCH CENTER (株式会社ボゾリサーチセンター) is a Japanese contract research organization (CRO) founded in 1972 by Hisashi Yamauchi, specializing in non-clinical safety and toxicity testing for pharmaceutical, medical device, food, agricultural chemical, and chemical substance manufacturers. The company operates four domestic research institutes (Gotemba, Kannami, Tsukuba, Tokyo) and one overseas facility (ITR Canada), offering GLP-compliant services across genotoxicity (Ames tests, chromosome aberration, micronucleus, comet assays), general safety studies, reproductive and developmental toxicity, carcinogenicity, safety pharmacology, pathology, and bio-medicine development support. BoZo holds five distinct GLP certifications (pharmaceutical, medical device, agricultural chemical, chemical substance, regenerative medicine) plus AAALAC International full accreditation, with study data accepted by Japanese (PMDA), US (FDA), and EU regulatory authorities.

The company generates revenue primarily through contract research services (professional services model) with custom quotations per study and multi-year contract cadences, complemented by product sales of S9/cofactor reagents, pathology laboratory supplies, and formaldehyde mitigation equipment through subsidiary FarmA Co., Ltd. Go-to-market is direct enterprise field sales from the Tokyo headquarters (Shibuya office), targeting B2B clients with study director involvement from inquiry through final report delivery. The company serves five vertical segments — pharmaceutical (primary), food, chemical, agricultural chemical, and medical device — with cumulative commissioned studies exceeding 59,000 since founding and a workforce of 251-500 employees including 26+ PhD holders developed through company-sponsored doctoral programs.

BoZo is a privately held, family-controlled corporation with no disclosed venture capital, private equity, or public investment. Recent strategic emphasis has been on expanding adjacent service lines — including alternative testing methods (Vitrigel-EIT), biopharmaceutical support (E. coli protein expression, antibody production), and strategic partnerships (e.g., Sekisui Medical in 2022) — while maintaining its core GLP safety testing franchise.

Name

BOZO RESEARCH CENTER

Legal name

株式会社ボゾリサーチセンター

Website

https://bozo.co.jp

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

251–500 employees

Short description

BOZO RESEARCH CENTER is a Japanese contract research organization founded in 1972 that provides GLP-compliant non-clinical safety and toxicity testing for pharmaceutical, food, chemical, agricultural chemical, and medical device manufacturers across five research institutes including one overseas facility (ITR Canada).

Ownership category

akta.pro rank

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services (CRO): Core business providing safety testing and toxicity testing services on a contract basis to pharmaceutical, food, chemical, agricultural chemical, and medical device companies. Services include GLP-compliant studies for regulatory submissions.
2. Research Product Sales: Sale of toxicity testing related products including S9/Co-factor kits for Ames testing, rapid decalcification solutions (K-CX AT), tissue embedding media (Tissue Prep), formaldehyde neutralizing products, xylene substitutes (Hemo-De, Clear Plus), and specimen preservation containers (Histo Pack).

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

BOZO RESEARCH CENTER is a Contract Research Organization (CRO) that provides non-clinical safety and toxicity testing services on a contract basis. Its core offerings include GLP-compliant genotoxicity assays (Ames, chromosome aberration, micronucleus), general safety studies (acute, subacute, chronic, reproductive, developmental, carcinogenicity), safety pharmacology, histopathology, analytical testing, and pharmacology/efficacy studies for pharmaceutical, medical device, food, agricultural chemical, and chemical substance manufacturers. The company also sells related laboratory consumable products through its group company FarmA Co., Ltd.

Product overview

BOZO RESEARCH CENTER is a Contract Research Organization (CRO) offering comprehensive nonclinical safety and toxicity testing services. The company operates four domestic research institutes (Gotemba, Kannami, Tsukuba, Tokyo) and one overseas facility (ITR Canada). Core services include Ames testing, genotoxicity studies (chromosome aberration, micronucleus, comet assays), general safety studies, reproductive/developmental toxicity, carcinogenicity, pharmacology, and bio-medicine development support. Related products include S9/cofactor reagents for Ames testing, pathology laboratory supplies (Fume Raze air purification systems, formaldehyde mitigation products, embedding media, storage containers, decalcification solutions), and GLP-compliant archive services. The company also provides translation services and regulatory support, serving pharmaceutical, medical device, pesticide, food, and chemical industries.

Differentiator

Problem solved

Functional benefit

Brands

• Ames Testing Products: S9 and cofactor products for Ames testing including S9 FF-01-002, Cofactor FA FF-02-012, and S9/Cofactor set FE-03-001
• Fume Raze / Catch Series
• Xylene Alternative Products
• Tissue Prep
• Histo Pack
• Formalin Neutralization Products
• K-CX AT
• BoZo Total Support Service

Products and services

• Bacterial Reverse Mutation Test (Ames Test) / 復帰突然変異試験

Quantifiable outcome

• 59,000+ commissioned studies completed since founding
• +1 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered key and core.

• Sekisui Medical Co., Ltd. (積水メトロZeneca株式会社)keyStrategic or Co-development Partner · 7 November 2022BoZo Research Center signed a cooperation agreement with Sekisui Medical Co., Ltd. in November 2022. The partnership aims to provide comprehensive solutions combining pharmacokinetics testing with non-clinical research studies. Joint webinars are conducted to educate clients on combined service offerings, including EFD (Embryo-Fetal Development) testing using mice and zebrafish teratogenicity testing.
• ITR CanadacoreStrategic or Co-development PartnerFirst overseas research institute established by a Japanese contract research organization. Provides international regulatory submission support, conducts tests not available in Japan, and enables market access support for North American and European markets. Pathology department serves as hub for information and personnel exchange.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

Market position

Weaknesses4 records

Competitive moat6 records

Customer concentration

• Facebookfacebook.com/pages/%E3%83%9C%E3%82%BE%E3%83%AA%E3%82%B5%E3%83%BC%E3%83%81%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC/546465418763616?fref=ts
• LinkedInlinkedin.com/company/bozo-research-center

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BOZO RESEARCH CENTER